BR112014013985A2 - formulações orais para tratamento de sobrecarga de metal - Google Patents

formulações orais para tratamento de sobrecarga de metal

Info

Publication number
BR112014013985A2
BR112014013985A2 BR112014013985A BR112014013985A BR112014013985A2 BR 112014013985 A2 BR112014013985 A2 BR 112014013985A2 BR 112014013985 A BR112014013985 A BR 112014013985A BR 112014013985 A BR112014013985 A BR 112014013985A BR 112014013985 A2 BR112014013985 A2 BR 112014013985A2
Authority
BR
Brazil
Prior art keywords
oral formulations
metal
treatment
metal overload
overload treatment
Prior art date
Application number
BR112014013985A
Other languages
English (en)
Inventor
Y Rienhoff Hugh Jr
Original Assignee
Ferrokin Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48574916&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112014013985(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ferrokin Biosciences Inc filed Critical Ferrokin Biosciences Inc
Publication of BR112014013985A2 publication Critical patent/BR112014013985A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/08—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D277/12—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/04—Chelating agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

resumo formulações orais para tratamento de sobrecarga de metal a presente invenção fornece, entre outras coisas, formulações orais eficazes baseadas em análogos do poliéter de desazadesferritiocina (dadft-pe), sais e polimorfos do mesmo, bem como sua aplicação para o tratamento da sobrecarga de metal, em particular, sobrecarga de ferro e doenças, distúrbios e condições associadas.
BR112014013985A 2011-12-09 2012-12-07 formulações orais para tratamento de sobrecarga de metal BR112014013985A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161568914P 2011-12-09 2011-12-09
US201161568890P 2011-12-09 2011-12-09
PCT/US2012/068432 WO2013086312A1 (en) 2011-12-09 2012-12-07 Oral formulations for treating metal overload

Publications (1)

Publication Number Publication Date
BR112014013985A2 true BR112014013985A2 (pt) 2017-06-13

Family

ID=48574916

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014013985A BR112014013985A2 (pt) 2011-12-09 2012-12-07 formulações orais para tratamento de sobrecarga de metal

Country Status (9)

Country Link
US (1) US8993606B2 (pt)
EP (1) EP2787994A4 (pt)
JP (1) JP2015500294A (pt)
AR (1) AR089122A1 (pt)
AU (1) AU2012347595A1 (pt)
BR (1) BR112014013985A2 (pt)
CA (1) CA2857990A1 (pt)
TW (1) TW201338777A (pt)
WO (1) WO2013086312A1 (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2012352025B2 (en) 2011-12-16 2018-01-18 University Of Florida Research Foundation, Inc. Uses of 4'-desferrithiocin analogs
EP2970162A1 (en) 2013-03-15 2016-01-20 Ferrokin Biosciences, Inc. Polymorph forms of desazadesferrithiocin analogs
EP3071201A4 (en) * 2013-11-22 2017-04-26 University of Florida Research Foundation, Inc. Desferrithiocin analogs and uses thereof
KR20170140306A (ko) 2015-04-27 2017-12-20 유니버시티 오브 플로리다 리서치 파운데이션, 인코포레이티드 대사적으로 프로그램화된 금속 킬레이트화제 및 그의 용도
WO2018104130A1 (en) 2016-12-07 2018-06-14 Lumileds Holding B.V. Flash light emitter with remote communication function
BR112022001062A2 (pt) * 2019-07-19 2022-03-15 Vifor Int Ag Inibidores de ferroportina para o uso no tratamento de beta-talassemia dependente de transfusão (tdt)
MX2023008515A (es) 2021-01-20 2023-07-27 Vifor Int Ag Inhibidores de ferroportina para su uso en el tratamiento de sindromes mielodisplasicos (smd).

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0610644B8 (pt) 2005-04-04 2021-05-25 Univ Florida composto e composição farmacêutica que compreende tal composto e um veículo ou diluente farmaceuticamente aceitável.
US8067451B2 (en) * 2006-07-18 2011-11-29 Horizon Pharma Usa, Inc. Methods and medicaments for administration of ibuprofen
NZ579994A (en) 2007-03-15 2011-09-30 Univ Florida Desferrithiocin polyether analogues useful in the treatment of pathological conditions responsive to chelation or sequestration of trivalent metal
NZ590302A (en) * 2008-07-14 2013-02-22 Ferrokin Biosciences Inc Novel salts and polymorphs of desazadesferrithiocin polyether analogues as metal chelation agents
CN102648189A (zh) 2009-07-27 2012-08-22 费罗金生物科学股份有限公司 作为金属螯合剂的脱氮杂去铁硫辛聚醚类似物的前药
JP5925679B2 (ja) 2009-08-25 2016-05-25 ユニバーシティ オブ フロリダ リサーチ ファウンデーション，インコーポレイティド デスフェリチオシンポリエーテル類似体およびその使用
AU2011248158A1 (en) 2010-05-04 2012-12-20 Ferrokin Biosciences, Inc. Desazadesferrothiocin and desazadesferrothiocin polyether analogues as metal chelation agents

Also Published As

Publication number Publication date
EP2787994A4 (en) 2015-08-26
US20130225645A1 (en) 2013-08-29
WO2013086312A1 (en) 2013-06-13
TW201338777A (zh) 2013-10-01
AR089122A1 (es) 2014-07-30
JP2015500294A (ja) 2015-01-05
EP2787994A1 (en) 2014-10-15
CA2857990A1 (en) 2013-06-13
AU2012347595A1 (en) 2014-06-26
US8993606B2 (en) 2015-03-31

Similar Documents

Publication Publication Date Title
IL284530A (en) RNAI factors, compositions and methods of using them for the treatment of transthyretin-related diseases
BR112014013985A2 (pt) formulações orais para tratamento de sobrecarga de metal
MX2020001602A (es) Inhibidor del antigeno-1 asociado a la funcion del linfocito (lfa-1) y polimorfo del mismo.
BR112016009889A2 (pt) ?compostos agonistas duplos gip-glp-1 e métodos?
EA201891833A1 (ru) Комбинация для лечения амиотрофического бокового склероза или родственных болезней
CO6930356A2 (es) Compuestos inhibidores de metaloenzimas
CO6940374A2 (es) Composiciones, usos y métodos para tratamiento de trastornos y enfermedades metabólicas
UY33627A (es) Compuestos para tratar enfermedades neurodegenerativas
BR112015027055A8 (pt) bi-heteroarilas, usos das mesmas, e composição farmacêutica
EA033067B1 (ru) Способ лечения метаболических расстройств у пациента, имеющего противопоказание к назначению бигуанидного соединения
BR112014030330A2 (pt) lentes oftálmicas levando em consideração a lateralidade do usuário
DK2877184T3 (da) Sammensætninger og behandling for øjensygdomme og -lidelser
BR112015000329A2 (pt) formulações de diclofenac
MX349224B (es) Composicion farmaceutica para uso en el tratamiento de una enfermedad neurodegenerativa.
EA201600442A1 (ru) Мягкая фармацевтическая композиция на водной основе, содержащая тапентадол
BR112013022052A2 (pt) ligantes antagonísticos de dr3
BR112014005935A2 (pt) derivados de anilina, sua preparação e sua aplicação terapêutica
MX357656B (es) Alfa-1-microglobulina para usarse en tratamiento de enfermedades relacionadas a mitocondrias.
GB201302343D0 (en) Pharmaceutical compositions comprising 15-OHEPA and methods for using the same
BR112015016033A2 (pt) composições e métodos para tratamento de infecções por bactérias
ECSP13012603A (es) Nueva formulacion del cetp(1)
GB2515440A (en) Vesicular formulations
CY1118255T1 (el) Υποκατεστημενα 6-αμινο-νικοτιναμιδια τα οποια φερουν μια ομαδα που περιεχει οη ως διαμορφωτες των kcnq2/3
EA201400970A1 (ru) Новые композиции для лечения амиотрофического бокового склероза
TR201106224A2 (tr) Solunum yolu hastalıkları tedavisinde kullanılan farmasötik bileşimler.

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B08F Application fees: application dismissed [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2494 DE 23-10-2018 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.

B350 Update of information on the portal [chapter 15.35 patent gazette]